{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-21-015239","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2021-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.096834+00:00","generated_at":"2026-06-29T23:15:48.863248+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Esperion Q2 net loss $43.7M; NEXLETOL/NEXLIZET net product revenue $10.6M up 67% QoQ","bullets":["U.S. net product revenue $10.6M, up 67% sequentially; prescriptions grew 28% during quarter.","Net loss $43.7M ($1.67/share) vs net income $124.6M in Q2 2020 on decline in milestone revenue.","Total revenue $40.7M (vs $212.2M Q2 2020); collaboration revenue fell due to lack of milestone payments.","Cash $219.2M at June 30; 2021 full-year operating expense guidance $320M-$340M.","Director Daniel Janney resigned effective July 28; Nicole Vitullo appointed to Audit Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-21-015239","json":"https://secwatch.observer/filing/0001628280-21-015239.json","markdown":"https://secwatch.observer/filing/0001628280-21-015239.md","text":"https://secwatch.observer/filing/0001628280-21-015239.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828021015239/0001628280-21-015239-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828021015239/espr-20210728.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T23:15:48.863248+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4644e72ec2","claim":"Daniel Janney resigned as Director at Esperion Therapeutics, Inc..","evidence_excerpt":"On July 28, 2021, Daniel Janney notified the Board of Directors of the Company of his decision to resign from the Company’s Board of Directors, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828021015239/0001628280-21-015239-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}